For the Inventor, By the Inventor

Enter assignee name

Gyeonggi-Do, South Korea

Intron Biotechnology, Inc.

Calculating rank

USPTO Granted Patents = 69

% Expired Patents = 2.9

EPO Patents = 10

Trademarks = 6

Forward Citations = 100

Loading Chart...

Loading Chart...

84 inventors (with patents filed for the assignee):

Seong Jun Yoon (47 out of 48 patents)

SAng Hyeon Kang (46 out of 71 patents)

Soo Youn Jun (45 out of 46 patents)

4. Jee Soo Son (25 out of 25 patents)

5. Hyoun Rok Paik (18 out of 18 patents)

6. Seongjun Yoon (14 out of 14 patents)

7. Sanghyeon Kang (14 out of 14 patents)

8. An Sung Kwon (12 out of 13 patents)

9. Sooyoun Jun (9 out of 9 patents)

10. Soon Hye Hwang (8 out of 8 patents)

11. Jeesoo Son (8 out of 8 patents)

12. Hyoung Rok Paik (7 out of 7 patents)

13. Yunjaie Choi (7 out of 7 patents)

14. In Hwang Kim (7 out of 7 patents)

15. Hee Jeong Shin (7 out of 7 patents)

Core Competencies:

Antibacterial Protein

Bacteriophage

Clostridium

Vibrio

Gram Negative

Heme Iron

PCR Method

Magnetic Resonance Imaging

Biological Method

Composition

Peptide Compound

Staphylococcal Infections

69 patents: Sort by Forward Citations

1. 12503494 - ANTIBACTERIAL PROTEIN CDL200 HAVING LYTIC ACTIVITY AGAINST CLOSTRIDIOIDES DIFFICILE (2025-12-23),

2. 12358953 - Antibacterial protein having lytic activity togenus and method for preparing the same (2025-07-15),

3. 12280081 - Compositions and methods for inhibiting the proliferation of enterotoxigenic (2025-04-21),

4. 12274721 - Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis (2025-04-14),

5. 12263196 - Compositions and methods for inhibiting the proliferation of enterotoxigenic (2025-04-01),

6. 12114664 - bacteriophage STP-2 and use thereof for inhibiting proliferation of (2024-10-15),

7. 11970700 - Genetic element E3 for enhanced intracellular expression of target protein encoded in RNA therapeutics (2024-04-30),

8. 11701398 - Compositions and methods for inhibiting the proliferation of pathogenic (2023-07-18),

9. 11679138 - Vibrio parahaemolyticus bacteriophage Vib-PAP-7 and use of same for inhibiting vibrio parahaemolyticus bacteria proliferation (2023-06-20),

10. 11679137 - bacteriophage Vib-PAP-4 and use thereof in inhibiting proliferation ofbacteria (2023-06-20),

11. 11596659 - Compositions and methods for inhibiting the proliferation of pathogenic (2023-03-07),

12. 11583565 - Compositions and methods for inhibiting the proliferation of pathogenic (2023-02-21),

13. 11548917 - Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same (2023-01-10),

14. 11529406 - bacteriophage Clo-PEP-2 and use for inhibitingproliferation of same (2022-12-20),

15. 11497216 - bacteriophage pse-AEP-4 and use thereof for inhibiting proliferation of (2022-11-15),

Company Overview

Intron Biotechnology, Inc., based in Gyeonggi-Do, South Korea, specializes in the development of innovative antibacterial proteins. The company focuses on harnessing the potential of bacteriophages and other advanced technologies to combat bacterial infections, particularly those caused by Gram-negative pathogens such as Clostridium and Vibrio. In addition to its core research in antibacterial solutions, Intron Biotechnology is also involved in the application of techniques like PCR and magnetic resonance imaging to enhance diagnostic and therapeutic outcomes in healthcare.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

69 Patents

#18 in Gyeonggi-Do

#250 in South Korea

#10,775 in the World

Gyeonggi-Do, South Korea

Intron Biotechnology, Inc.

Forward Citations = 100

84 inventors:

Seong Jun Yoon (47 out of 48 patents)

SAng Hyeon Kang (46 out of 71 patents)

Soo Youn Jun (45 out of 46 patents)

4. Jee Soo Son (25 out of 25 patents)

5. Hyoun Rok Paik (18 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Intron Biotechnology, Inc.. Retrieved from https://idiyas.com/company/intron-biotechnology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…